Targeted PET-MR imaging of novel biomarkers: assessing pain, cancer and other neurological disorders
- Friday, October 19 at 2:15pm
- Communicore, C1-4
- Hosted by the Department of Medicinal Chemistry and the McKnight Brain Institute
Dr. Frederick T. Chin is an Assistant Professor in the Department of Radiology at Stanford University and the Director of the Cyclotron and Radiochemistry Program. Dr. Chin has nearly 25 years of experience in the field of radiopharmaceutical and tracer development for molecular imaging. Dr. Chin completed an NIH postdoctoral fellow in the National Institute of Mental Health where he made and developed many radiopharmaceuticals that were used to study neuropsychiatric-related disorders such stress, anxiety and Alzheimer’s disease. As Director of the Cyclotron and Radiochemistry Facility since 2005, he supervises the program development of PET/SPECT probes for molecular imaging at Stanford, which involves more than 30 radiochemistry/chemistry personnel including faculty, staff, postdocs and graduate students. Dr. Chin’s research areas of interest include developing new strategies for: 1) novel radioligand and radiotracer development for various targets involved in brain and cancer biology, 2) radiolabeling methods of molecules/peptides/antibodies, and 3) clinical translation of useful radiopharmaceuticals for early-detection of disease and monitoring therapy. Dr. Chin continues to develop novel tracers for positron emission tomography and have translated over 40 radiolabeled compounds for clinical imaging in his career. He is currently leading two PET-MR centric projects including a NIH R01 funded project entitled “Cross-Species Multi-Modal Neuroimaging to Investigate GABA Physiology in Fragile X Syndrome” as well as his first-in-human studies using clinical grade 18F-FTC-146 used for imaging sigma-1 receptors (S1Rs).
